Open AccessMinimal manifestation status and prednisone withdrawal in the MGTX trial
Author(s) -
Ik Jae Lee,
Hui-Chien Kuo,
Inmaculada Aban,
Gary Cutter,
Tarrant McPherson,
Henry J. Kaminski,
Jon Sussman,
Philipp Ströbel,
Joël Oger,
Gabriel Cea,
Jeannine M Heckmann,
Amelia Evoli,
Wilfred A. Nix,
Emma Ciafaloni,
Giovanni Antonini,
Rawiphan Witoonpanich,
John King,
Said R. Beydoun,
Colin Chalk,
Alexandru Barboi,
Anthony A. Amato,
Aziz Shaibani,
Bashar Katirji,
Bryan Lecky,
Camilla Buckley,
Angela Vincent,
Elza DiasTosta,
Hiroaki Yoshikawa,
Márcia Waddington-Cruz,
Michael Pulley,
Michael H. Rivner,
Anna KosteraPruszczyk,
Robert M. Pascuzzi,
Carlayne Jackson,
Jan J. Verschuuren,
Janice M. Massey,
John T. Kissel,
Lineu César Werneck,
Michael Benatar,
Richard J. Barohn,
Rup Tandan,
Tahseen Mozaffar,
Robin Conwit,
Greg Minisman,
Joshua R. Sonett,
Gil I. Wolfe
Publication year - 2020
Publication title -
neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.91
H-Index - 364
eISSN - 1526-632X
pISSN - 0028-3878
DOI - 10.1212/wnl.0000000000010031
Subject(s) - prednisone , thymectomy , myasthenia gravis , medicine , thymoma , randomized controlled trial , corticosteroid , surgery , gastroenterology
To examine whether sustained minimal manifestation status (MMS) with complete withdrawal of prednisone is better achieved in thymectomized patients with myasthenia gravis (MG).